HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 30, 2007--Acorda
Therapeutics, Inc. (Nasdaq: ACOR) announced today that it has
completed enrollment for its Phase 3 clinical trial of Fampridine-SR
in multiple sclerosis (MS). The trial is designed to evaluate the
safety and efficacy of Fampridine-SR in improving walking ability in
people with MS. 240 patients were enrolled at 39 clinical trial sites
in the United States and Canada. The Company expects data from the
trial in the second quarter of 2008.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing
therapies for spinal cord injury, multiple sclerosis and related
nervous system disorders. The Company's marketed products include
Zanaflex CapsulesTM (tizanidine hydrochloride), a short-acting drug
for the management of spasticity. Acorda's lead clinical product,
Fampridine-SR, is in a Phase 3 clinical trial to evaluate its safety
and efficacy in improving walking ability in people with MS. The
Company's pipeline includes a number of products in development for
the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should
be considered forward-looking. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially, including Acorda Therapeutics' ability to successfully
market and sell Zanaflex Capsules, the risk of unfavorable results
from future studies of Fampridine-SR, delays in obtaining or failure
to obtain FDA approval of Fampridine-SR, competition, failure to
protect its intellectual property or to defend against the
intellectual property claims of others, the ability to obtain
additional financing to support Acorda Therapeutics' operations, and
unfavorable results from its preclinical programs. These and other
risks are described in greater detail in Acorda Therapeutics' filings
with the Securities and Exchange Commission. Acorda Therapeutics may
not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Acorda Therapeutics disclaims any intent
or obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.
CONTACT: Acorda Therapeutics
tsaccavino@acorda.com
SOURCE: Acorda Therapeutics, Inc.